Copy to clipboard 
Orthofix reported 2Q25 orthopedic sales of $203.1 million, up 2.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $396.8 million in orthopedic sales, up 2.5% compared to the prior period.
Spinal fixation sales in the U.S. grew in the mid-single digits, consistent with the company’s expectations as it works through a targeted distributor transition. Orthofix believes its new distribution will bring a sizeable book of business and support an above-market CAGR between 6.5% and 7.5%.
The Voyager Earn Out program for the 7D navigation system helped Orthofix grow its U.S. system placements by 66% in the first half of 2025 compared to the first half of 2024. The company said its earn out customers are exceeding contracted spinal hardware and orthobiologic purchase commitments by 50% on average.
Orthofix’s U.S. trauma business grew by 28% in the second quarter, marking the fourth consecutive quarter of double-digit growth.
Trauma performance was boosted by the TrueLok Elevate Transverse Bone Transport System, which has completed 200 cases since receiving FDA clearance and CE mark registration earlier this year. The company is focused on being the market leader in complex limb reconstruction.
“Our unique position as the only company in the U.S., offering a complete suite of internal and external limb reconstruction solution is yielding substantial results,” said Orthofix CEO Massimo Calafiore. “This dedicated focus on limb reconstruction is expected to be a crucial growth engine for Orthofix for many years to come as we aim to become the global leader in this $1.7 billion market.”
The company reiterated its 2025 revenue guidance of sales between $808 million and $816 million, excluding the impact of the divested M6 product line.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $68.7 | $70.5 | ($1.8) | (2.5%) |
| Trauma | $33.3 | $30.6 | $2.7 | 8.9% |
| Orthobiologics | $35.8 | $35.9 | ($0.1) | (0.3%) |
| Enabling Technology | $2.7 | $2.5 | $0.2 | 9.4% |
| Other (Bone Growth Therapies) | $62.6 | $59.1 | $3.4 | 5.8% |
| Total | $203.1 | $198.6 | $4.5 | 2.3% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $142.1 | $142.9 | ($0.8) | (0.6%) |
| Trauma | $63.1 | $57.9 | $5.2 | 9% |
| Orthobiologics | $69.5 | $70.8 | ($1.2) | (1.7%) |
| Enabling Technology | $4.4 | $4.1 | $0.3 | 8.3% |
| Other (Bone Growth Therapies) | $117.6 | $111.6 | $6.0 | 5.4% |
| Total | $396.8 | $387.2 | $9.5 | 2.5% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $171.7 | $166.9 | $4.8 | 2.9% |
| OUS | $31.4 | $31.7 | ($0.3) | (1%) |
| EMEA | $14.2 | $13.8 | $0.4 | 3.1% |
| ROW | $17.2 | $17.9 | ($0.7) | (4.1%) |
| Total | $203.1 | $198.6 | $4.5 | 2.3% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $333.4 | $327.0 | $6.5 | 2% |
| OUS | $63.3 | $60.3 | $3.1 | 5.1% |
| EMEA | $27.1 | $26.0 | $1.1 | 4.2% |
| ROW | $36.2 | $34.2 | $2.0 | 5.8% |
| Total | $396.8 | $387.2 | $9.5 | 2.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $203.1 | |
| Cost of Sales | $63.6 | 31.3% |
| General and Admin | $136.5 | 67.2% |
| R & D | $15.9 | 7.8% |
| Other | $1.2 | 0.6% |
| Net Earnings | ($14.1) | (6.9%) |
Orthofix reported 2Q25 orthopedic sales of $203.1 million, up 2.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $396.8 million in orthopedic sales, up 2.5% compared to the prior period.
Spinal fixation sales in the U.S. grew in the mid-single digits, consistent with the company's expectations as...
Orthofix reported 2Q25 orthopedic sales of $203.1 million, up 2.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $396.8 million in orthopedic sales, up 2.5% compared to the prior period.
Spinal fixation sales in the U.S. grew in the mid-single digits, consistent with the company’s expectations as it works through a targeted distributor transition. Orthofix believes its new distribution will bring a sizeable book of business and support an above-market CAGR between 6.5% and 7.5%.
The Voyager Earn Out program for the 7D navigation system helped Orthofix grow its U.S. system placements by 66% in the first half of 2025 compared to the first half of 2024. The company said its earn out customers are exceeding contracted spinal hardware and orthobiologic purchase commitments by 50% on average.
Orthofix’s U.S. trauma business grew by 28% in the second quarter, marking the fourth consecutive quarter of double-digit growth.
Trauma performance was boosted by the TrueLok Elevate Transverse Bone Transport System, which has completed 200 cases since receiving FDA clearance and CE mark registration earlier this year. The company is focused on being the market leader in complex limb reconstruction.
“Our unique position as the only company in the U.S., offering a complete suite of internal and external limb reconstruction solution is yielding substantial results,” said Orthofix CEO Massimo Calafiore. “This dedicated focus on limb reconstruction is expected to be a crucial growth engine for Orthofix for many years to come as we aim to become the global leader in this $1.7 billion market.”
The company reiterated its 2025 revenue guidance of sales between $808 million and $816 million, excluding the impact of the divested M6 product line.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $68.7 | $70.5 | ($1.8) | (2.5%) |
| Trauma | $33.3 | $30.6 | $2.7 | 8.9% |
| Orthobiologics | $35.8 | $35.9 | ($0.1) | (0.3%) |
| Enabling Technology | $2.7 | $2.5 | $0.2 | 9.4% |
| Other (Bone Growth Therapies) | $62.6 | $59.1 | $3.4 | 5.8% |
| Total | $203.1 | $198.6 | $4.5 | 2.3% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $142.1 | $142.9 | ($0.8) | (0.6%) |
| Trauma | $63.1 | $57.9 | $5.2 | 9% |
| Orthobiologics | $69.5 | $70.8 | ($1.2) | (1.7%) |
| Enabling Technology | $4.4 | $4.1 | $0.3 | 8.3% |
| Other (Bone Growth Therapies) | $117.6 | $111.6 | $6.0 | 5.4% |
| Total | $396.8 | $387.2 | $9.5 | 2.5% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $171.7 | $166.9 | $4.8 | 2.9% |
| OUS | $31.4 | $31.7 | ($0.3) | (1%) |
| EMEA | $14.2 | $13.8 | $0.4 | 3.1% |
| ROW | $17.2 | $17.9 | ($0.7) | (4.1%) |
| Total | $203.1 | $198.6 | $4.5 | 2.3% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $333.4 | $327.0 | $6.5 | 2% |
| OUS | $63.3 | $60.3 | $3.1 | 5.1% |
| EMEA | $27.1 | $26.0 | $1.1 | 4.2% |
| ROW | $36.2 | $34.2 | $2.0 | 5.8% |
| Total | $396.8 | $387.2 | $9.5 | 2.5% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $203.1 | |
| Cost of Sales | $63.6 | 31.3% |
| General and Admin | $136.5 | 67.2% |
| R & D | $15.9 | 7.8% |
| Other | $1.2 | 0.6% |
| Net Earnings | ($14.1) | (6.9%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
